IL325613A - נוגדנים כנגד פקטור xii/xiia והשימושים בהם - Google Patents
נוגדנים כנגד פקטור xii/xiia והשימושים בהםInfo
- Publication number
- IL325613A IL325613A IL325613A IL32561325A IL325613A IL 325613 A IL325613 A IL 325613A IL 325613 A IL325613 A IL 325613A IL 32561325 A IL32561325 A IL 32561325A IL 325613 A IL325613 A IL 325613A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- amino acid
- antigen
- fxii
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363514392P | 2023-07-19 | 2023-07-19 | |
| PCT/US2024/038781 WO2025019789A1 (en) | 2023-07-19 | 2024-07-19 | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325613A true IL325613A (he) | 2026-02-01 |
Family
ID=92302431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325613A IL325613A (he) | 2023-07-19 | 2024-07-19 | נוגדנים כנגד פקטור xii/xiia והשימושים בהם |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR20260042526A (he) |
| CN (1) | CN121568964A (he) |
| AU (1) | AU2024291721A1 (he) |
| CO (1) | CO2026001497A2 (he) |
| IL (1) | IL325613A (he) |
| MX (1) | MX2026000675A (he) |
| WO (1) | WO2025019789A1 (he) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CA2591786C (en) | 2004-12-23 | 2013-07-16 | Bernhard Nieswandt | Prevention of thrombus formation and/or stabilization |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
| CN103415301A (zh) | 2011-03-09 | 2013-11-27 | 德国杰特贝林生物制品有限公司 | 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂 |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| ES3005912T3 (en) | 2011-07-22 | 2025-03-17 | Csl Behring Gmbh | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| WO2014089493A1 (en) | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN116333144A (zh) * | 2015-07-21 | 2023-06-27 | 武田药品工业株式会社 | 一种因子xiia的单克隆抗体抑制剂 |
| MA52966A (fr) * | 2018-06-19 | 2021-04-28 | Regeneron Pharma | Anticorps anti-facteur xii/xiia et leurs utilisations |
| AU2020396054A1 (en) * | 2019-12-03 | 2022-07-07 | CSL Innovation Pty Ltd | Use of an anti-Factor XII antibody for the treatment or prevention of hereditary angioedema |
-
2024
- 2024-07-19 IL IL325613A patent/IL325613A/he unknown
- 2024-07-19 AU AU2024291721A patent/AU2024291721A1/en active Pending
- 2024-07-19 CN CN202480047053.0A patent/CN121568964A/zh active Pending
- 2024-07-19 WO PCT/US2024/038781 patent/WO2025019789A1/en active Pending
- 2024-07-19 KR KR1020267004844A patent/KR20260042526A/ko active Pending
-
2026
- 2026-01-16 MX MX2026000675A patent/MX2026000675A/es unknown
- 2026-02-10 CO CONC2026/0001497A patent/CO2026001497A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026000675A (es) | 2026-03-02 |
| WO2025019789A1 (en) | 2025-01-23 |
| CO2026001497A2 (es) | 2026-02-23 |
| AU2024291721A1 (en) | 2026-01-22 |
| CN121568964A (zh) | 2026-02-24 |
| KR20260042526A (ko) | 2026-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230174631A1 (en) | Anti-c5 antibodies and uses thereof | |
| JP2024116399A (ja) | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 | |
| US20250333524A1 (en) | Immunoglobulin proteins that bind to npr1 agonists | |
| IL325613A (he) | נוגדנים כנגד פקטור xii/xiia והשימושים בהם | |
| US20240190996A1 (en) | Factor xi catalytic domain-binding antibodies and methods of use thereof | |
| US12304969B2 (en) | Factor XI A2 domain-binding antibodies and methods of use thereof | |
| EA048528B1 (ru) | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ | |
| EA052707B1 (ru) | Антитела, связывающие домен a2 фактора xi, и способы их использования | |
| JP2025138816A (ja) | 骨形成タンパク質６に対するヒト抗体 | |
| EA053011B1 (ru) | Иммуноглобулиновые белки, связывающиеся с агонистами npr1 |